Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

(2012) I.-M. Chen et al.   BLOOD

Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

(2012) Smita Bhatia et al.   JOURNAL OF CLINICAL ONCOLOGY

ARID5BGenetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia

(2012) Heng Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007

(2012) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

(2012) Stephen P. Hunger et al.   JOURNAL OF CLINICAL ONCOLOGY

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

The Pediatric Cancer Genome Project

(2012) James R Downing et al.   NATURE GENETICS

Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia

(2012) Martin Schrappe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

(2011) A. Willer et al.   BLOOD

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

(2011) J. D. Kawedia et al.   BLOOD

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

(2011) M. Schrappe et al.   BLOOD

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2011) Y. Matloub et al.   BLOOD

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)

(2011) B. L. Asselin et al.   BLOOD

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study

(2011) H. Kang et al.   BLOOD

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2011) J. Zhang et al.   BLOOD

Acute lymphoblastic leukaemia in children with Down syndrome: an updated review

(2011) Kelly W. Maloney   BRITISH JOURNAL OF HAEMATOLOGY

Does octreotide prevent l-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?

(2011) Sadao Tokimasa et al.   BRITISH JOURNAL OF HAEMATOLOGY

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols

(2011) Rachael F. Grace et al.   BRITISH JOURNAL OF HAEMATOLOGY

Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia

(2011) Kirsten K. Ness et al.   CANCER

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

(2011) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial

(2011) Torben S. Mikkelsen et al.   JOURNAL OF CLINICAL ONCOLOGY

Leukokoria: All That's White Is Not Retinoblastoma

(2011) Seema A. Kembhavi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

(2011) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia

(2011) Jana Hof et al.   JOURNAL OF CLINICAL ONCOLOGY

Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update

(2011) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

(2011) D Bhojwani et al.   LEUKEMIA

CREBBP mutations in relapsed acute lymphoblastic leukaemia

(2011) Charles G. Mullighan et al.   NATURE

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

(2011) Jun J Yang et al.   NATURE GENETICS

Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

(2011) Christine M. Mrakotsky et al.   PEDIATRIC BLOOD & CANCER

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

(2010) L. C. Stork et al.   BLOOD

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol

(2010) G. Cario et al.   BLOOD

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

(2010) R. C. Harvey et al.   BLOOD

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

(2010) R. C. Harvey et al.   BLOOD

Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial

(2010) H. M. Ensor et al.   BLOOD

Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting

(2010) E. Schafer et al.   BLOOD

L-asparaginase treatment in acute lymphoblastic leukemia

(2010) Rob Pieters et al.   CANCER

Pharmacogenomics in pediatric leukemia

(2010) Steven W Paugh et al.   CURRENT OPINION IN PEDIATRICS

Glucocorticoid use in acute lymphoblastic leukaemia

(2010) Hiroto Inaba et al.   LANCET ONCOLOGY

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

(2010) Anthony V Moorman et al.   LANCET ONCOLOGY

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL

(2010) R P Kuiper et al.   LEUKEMIA

Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk

(2010) Amy L Sherborne et al.   NATURE GENETICS

A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia

(2009) N. S. Kadan-Lottick et al.   BLOOD

Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options

(2009) D. J. P. M. Stumpel et al.   BLOOD

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

(2009) K. Schmiegelow et al.   BLOOD

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)

(2009) I. Iacobucci et al.   BLOOD

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

(2009) L. Hertzberg et al.   BLOOD

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

(2009) L. J. Russell et al.   BLOOD

IKZF1(Ikaros) Deletions inBCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

(2009) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Late-Occurring Neurologic Sequelae in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study

(2009) Robert E. Goldsby et al.   JOURNAL OF CLINICAL ONCOLOGY

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

(2009) Elaine Coustan-Smith et al.   LANCET ONCOLOGY

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

(2009) Monique L Den Boer et al.   LANCET ONCOLOGY

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)

(2009) Anjo J Veerman et al.   LANCET ONCOLOGY

Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1

(2009) S Jeha et al.   LEUKEMIA

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

(2009) K Schmiegelow et al.   LEUKEMIA

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)

(2009) L B Silverman et al.   LEUKEMIA

Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001

(2009) C Mitchell et al.   LEUKEMIA

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

(2009) A Möricke et al.   LEUKEMIA

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia

(2009) V Conter et al.   LEUKEMIA

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report

(2009) P S Gaynon et al.   LEUKEMIA

Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

(2009) Charles G Mullighan et al.   NATURE GENETICS

Germline genomic variants associated with childhood acute lymphoblastic leukemia

(2009) Lisa R Treviño et al.   NATURE GENETICS

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia

(2009) Elli Papaemmanuil et al.   NATURE GENETICS

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis

(2009) Susan L. Kearney et al.   PEDIATRIC BLOOD & CANCER

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

(2009) A. Yoda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

(2008) L. Kearney et al.   BLOOD

Prevalence and clinical correlates ofJAK2mutations in Down syndrome acute lymphoblastic leukaemia

(2008) Amos Gaikwad et al.   BRITISH JOURNAL OF HAEMATOLOGY

Neuropsychological Outcome in Chemotherapy-Only–Treated Children With Acute Lymphoblastic Leukemia

(2008) Nathalie C.A.J. Jansen et al.   JOURNAL OF CLINICAL ONCOLOGY

Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia

(2008) Lei Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

(2008) Ching-Hon Pui et al.   LANCET ONCOLOGY

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE